Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). [PDF]
PLoS ONE, 2015 The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1, Kadcyla) has been approved by the U.S. FDA to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Yuan-Chiang Chung +4 more
doaj +1 more source
Progresses in research and development of antibody-drug conjugate
生物医学转化, 2021 Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized.
Wu Gang +6 more
doaj +1 more source
Aptamer-based therapeutics and their potential in radiopharmaceutical design [PDF]
, 2007 Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a plethora of targets and for a variety of applications.
Ferreira, Catia S. M. +1 more
core +3 more sources
mAbs, 2021 This study describes the characterization of conjugation sites for a random, lysine conjugated 2-iminothiolane (2-IT) based antibody-drug-conjugate synthesized from an IgG1 antibody and a duocarmycin analog-based payload-linker. Of the 80 putative lysine
Difei Qiu +4 more
doaj +1 more source
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements [PDF]
, 2009 IT-101, a cyclodextrin polymer-based nanoparticle containing camptothecin, is in clinical development for the treatment of cancer. Multiorgan pharmacokinetics and accumulation in tumor tissue of IT-101 is investigated by using PET.
Alley +33 more
core +3 more sources
Understanding the Toxicity Profile of Approved ADCs
PharmaceuticsBackground: Antibody–drug conjugates (ADCs) represent a novel therapeutic class that combines an antibody against a tumor-associated antigen (TAA), a payload, and a linker that binds these two components. Serious adverse events (SAEs), particularly those
Pablo Ballestín +9 more
doaj +1 more source
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
Biomolecules, 2020 The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or stimulate its activity is the basis for the rapid growth and development of the therapeutic antibody field.
Hyunbo Shim
doaj +1 more source
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
SLAS discovery : advancing life sciences R & D, 2020 The targeted delivery of potent cytotoxic molecules into cancer cells is considered a promising anticancer strategy. The design of clinically effective antibody–drug conjugates (ADCs), in which biologically active drugs are coupled through chemical ...
Laurence Gauzy-Lazo +2 more
semanticscholar +1 more source
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells _in vitro_ and _in vivo_ [PDF]
, 2008 CD138 (Syndecan1) is highly expressed on multiple myeloma (MM) cells. In this study, we examined the anti-MM effect of murine/human chimeric CD138-specific monoclonal antibody (mAb) nBT062 conjugated with highly cytotoxic maytansinoid derivatives _in ...
Benjamin Dä +20 more
core +1 more source
Nature Communications, 2018 The nature of the linker is known to affect the efficacy of antibody–drug conjugate (ADC). Here the authors show cetuximab-guided Avidin-Nucleic-Acid-Nanoassemblies to be superior to cetuximab-doxorubicin conjugate, and show its efficacy in KRAS mutant ...
Francesco Roncato +10 more
doaj +1 more source